BEAT HeartBeam, Inc.

Nasdaq heartbeam.com


$ 1.71 $ -0.04 (-2.26 %)    

Thursday, 16-Oct-2025 15:59:48 EDT
QQQ $ 598.23 $ -2.23 (-0.37 %)
DIA $ 458.84 $ -3.15 (-0.68 %)
SPY $ 658.90 $ -4.53 (-0.68 %)
TLT $ 91.49 $ 0.68 (0.75 %)
GLD $ 401.79 $ 9.06 (2.34 %)
$ 1.73
$ 1.80
$ 1.65 x 7
$ 1.84 x 7,198
$ 1.67 - $ 1.81
$ 0.91 - $ 3.48
51,854
na
59.36M
$ 0.48
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2025 06-30-2025 10-Q
2 05-13-2025 03-31-2025 10-Q
3 03-13-2025 12-31-2024 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-14-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 03-20-2024 12-31-2023 10-K
8 11-14-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 03-16-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-11-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 03-24-2022 12-31-2021 10-K
16 12-16-2021 09-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 heartbeam-q2-eps-015-inline
HeartBeam Q2 EPS $(0.15), Inline
08/13/2025 20:02:05

HeartBeam (NASDAQ:BEAT) reported quarterly losses of $(0.15) per share which met the analyst consensus estimate. This is a 21.0...

 heartbeam-to-share-cardiac-tech-vision-with-investors-at-iaccess-alpha-summer-conference

HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personal...

 heartbeam-q1-eps-018-misses-015-estimate

HeartBeam (NASDAQ:BEAT) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.15) b...

 heartbeam-announces-it-has-received-two-new-us-patents

First patent significantly advances intellectual property for HeartBeam's credit card-sized ECG device, bolstering both the...

 heartbeams-synthesized-12-lead-electrocardiogram-meets-clinical-endpoints-in-valid-ecg-pivotal-study

Milestone results formed the basis of HeartBeam's 12-lead ECG synthesis software application submitted to FDA in January 20...

 heartbeam-and-accurkardia-enters-strategic-collaboration-to-advance-cardiac-monitoring-innovation

Collaboration brings together two leaders in ambulatory ECG recording and analysisHeartBeam, Inc. (NASDAQ:BEAT), a medical tech...

 heartbeam-q4-2024-adj-eps-073-misses-019-estimate

HeartBeam (NASDAQ:BEAT) reported quarterly losses of $(0.73) per share which missed the analyst consensus estimate of $(0.19) b...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION